<SEC-DOCUMENT>0001193125-16-461555.txt : 20160212
<SEC-HEADER>0001193125-16-461555.hdr.sgml : 20160212
<ACCEPTANCE-DATETIME>20160212115136
ACCESSION NUMBER:		0001193125-16-461555
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20160210
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160212
DATE AS OF CHANGE:		20160212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcadia Biosciences, Inc.
		CENTRAL INDEX KEY:			0001469443
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		IRS NUMBER:				810571538
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37383
		FILM NUMBER:		161416496

	BUSINESS ADDRESS:	
		STREET 1:		202 COUSTEAU PLACE
		STREET 2:		SUITE 200
		CITY:			DAVIS
		STATE:			X1
		ZIP:			95618
		BUSINESS PHONE:		602-429-0476

	MAIL ADDRESS:	
		STREET 1:		4222 E. THOMAS RD
		STREET 2:		SUITE 320
		CITY:			PHOENIX
		STATE:			X1
		ZIP:			85018
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d139618d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report: February&nbsp;10, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arcadia
Biosciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-37383</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>81-0571538</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>202 Cousteau Place, Suite 105 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Davis, CA 95618 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Addresses of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(530) 756-7077 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>(b) Resignation of Officer </U></I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Resignation of Eric J. Rey as President, Chief Executive Officer, and Director </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, Eric J. Rey, President and Chief Executive Officer of Arcadia Biosciences, Inc. (the &#147;Company&#148;) and a
member of the Company&#146;s Board of Directors (the &#147;Board&#148;), and the Company mutually agreed to terminate his employment with the Company, and for Mr.&nbsp;Rey to resign his position as an officer of the Company and as a member of the
Board in order to allow Mr.&nbsp;Rey to focus on his health. Mr.&nbsp;Rey had been on a temporary medical leave of absence from his duties and responsibilities as the Company&#146;s President and Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Mr.&nbsp;Rey&#146;s departure, the Company entered into a Consulting Services, Separation Agreement and Release (the
&#147;Agreement&#148;) with Mr.&nbsp;Rey setting forth the terms and conditions of his transition services and departure from the Company. The Agreement contemplates that Mr.&nbsp;Rey will cease to be an officer of the Company and member of the
Board of Directors effective as of February&nbsp;11, 2016, but that Mr.&nbsp;Rey will remain an employee of the Company until March&nbsp;1, 2016 (the &#147;Separation Date&#148;). Following the Separation Date, he will provide transition services as
a consultant to the Company through February&nbsp;1, 2017, at a rate of $500 per hour for up to 10 hours a month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement provides
that Mr.&nbsp;Rey will receive severance payments for a period of 12 months from the Separation Date at a rate equal to his salary as in effect immediately prior to his resignation. During the term of his consulting services, his unvested stock
options will continue to vest. In addition, all equity awards previously issued to Mr.&nbsp;Rey shall be exercisable after the Separation Date until the original expiration date of each respective equity award. The Agreement further provides that
Mr.&nbsp;Rey will receive a $60,000 cash bonus for calendar year 2015; which bonus shall be paid at the next payroll period after receipt by the Company of an executed copy of the Agreement. As provided in the Agreement, Mr.&nbsp;Rey will also be
entitled to receive the benefits set forth in his existing severance agreement with the Company, subject to the terms of such severance agreement, in exchange for his general release of claims in favor of the Company. Mr.&nbsp;Rey has agreed to a
one year non-solicitation period and has agreed to release the Company from all claims, known and unknown, with normal exceptions. The foregoing description is qualified in its entirety by the text of the Agreement, which is filed as Exhibit 10.1 to
this Current Report on Form 8-K and incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expects to nominate a new Class I member of the Board
to replace Mr.&nbsp;Rey, for approval at the Company&#146;s 2016 annual meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Resignation of Mark W. Wong,
Director, Acting President and Chief Executive Officer </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;10, 2016, Mark W. Wong notified the Board that he would be
resigning from his positions as Acting President and Chief Executive Officer of the Company and member of the Board effective immediately in order to pursue other business opportunities. Mr.&nbsp;Wong felt that, due to outside business interests, he
was unable to make the necessary long-term commitment to the Company to continue to serve as Acting President and Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Wong confirmed that his resignation was not due to any disagreement with the Company on any matter relating to the Company&#146;s
operations, policies, or practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>(c) Appointment of New Officer </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>(e)&nbsp;Material Compensatory Plan for Executive Officer </U></I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Appointment of Roger Salameh as Interim President and Chief Executive Officer </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Board appointed Roger Salameh to serve as the Company&#146;s Interim President and Chief Executive Officer
while the Board conducts a search for a permanent President and Chief Executive Officer for the Company. Mr.&nbsp;Salameh will fulfill his duties and responsibilities in consultation and cooperation with the Board and the Company&#146;s executive
management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Salameh has served as the Company&#146;s Vice President of Business Development since November 2003. He has
more than 22 years of executive, managerial, and operations experience in agricultural, biotechnology, and food ingredients businesses. Prior to joining the Company, Mr.&nbsp;Salameh was a consultant with Rockridge. Before joining Rockridge, he
served as director of business development at Monsanto Company. Prior to Monsanto, Mr.&nbsp;Salameh served as product manager for Calgene, Inc.&#146;s genetically modified oils business. Mr.&nbsp;Salameh attended New York University where he studied
Economics and Political Science. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into revised compensation arrangements with Mr.&nbsp;Salameh, reflecting
his role as the Company&#146;s Interim President and Chief Executive Officer. Effective upon his appointment, Mr.&nbsp;Salameh&#146;s base compensation has been increased from $243,000 annually to $280,000 annually, with such increase to remain in
effect after a new CEO is appointed. For so long as Mr.&nbsp;Salameh is employed as the Interim President and Chief Executive Officer, he will also receive additional compensation of $10,000 per month, payable monthly in arrears. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>(d) Appointment of New Director and Appointment of New Board Committee Members </U></I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Appointment of Vic C. Knauf, Ph.D. to Board of Directors </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Board appointed Vic C. Knauf, Ph.D., to serve as a Class II director of the Company, effective immediately.
Dr.&nbsp;Knauf&#146;s appointment fills the Class II Board position left vacant by Mr.&nbsp;Wong&#146;s resignation from the Board. Dr.&nbsp;Knauf&#146;s term will expire at the annual meeting of the Company&#146;s stockholders in 2017.
Mr.&nbsp;Knauf will not receive additional compensation for serving as a director for so long as he continues to serve as an employee of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Knauf has served as the Company&#146;s Chief Scientific Officer since June 2005. He has 30 years of experience in agricultural
product and technology development. Prior to joining the Company, Dr.&nbsp;Knauf founded Anawah, Inc., a food and agricultural research company focused on the development of value-added whole foods, which the Company acquired in 2005. Before Anawah,
Dr.&nbsp;Knauf served as a Director of Monsanto Food and Nutrition Research and Vice President of Research at Calgene, Inc. Dr.&nbsp;Knauf holds a B.S. in Biology from the New Mexico Institute of Mining and Technology and a M.S. and Ph.D. in
Microbiology and Immunology from the University of Washington. The Company believes that Dr.&nbsp;Knauf is qualified to serve on the Board due to his extensive experience in agricultural product and technology development and his understanding of
the Company gained during more than ten years of service as its Chief Scientific Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Board of Directors Committee Appointments
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">George F.J. Gosbee, a current member of the Board, replaced Mr.&nbsp;Wong as a member of and chair of the Compensation Committee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has formed a special committee to search for a new president and Chief Executive Officer. Matthew A. Ankrum has agreed to serve
as chair of the CEO search committee, with Uday Garg and Rajiv Shah, M.D. serving as members. Darby E. Shupp, the Chairman of the Board, will serve as an <I>ex officio</I> member of the search committee. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Company issued a press
release announcing the management changes described above. A copy of the press release issued by the Company on February&nbsp;11, 2016 is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in Item&nbsp;7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed &#147;filed&#148; for
purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that Section unless the registrant specifically incorporates it by reference in a document filed under the Securities Act of 1933,
as amended, or the Securities Exchange Act of 1934, as amended. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consulting Services, Separation Agreement and Release between Arcadia Biosciences, Inc. and Eric J. Rey, dated February 11, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release issued by Arcadia Biosciences, Inc. entitled &#147;ARCADIA BIOSCIENCES ANNOUNCES DEPARTURE OF CEO FOR MEDICAL REASONS AND CHANGES IN BOARD OF DIRECTORS&#148; dated February 11, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ARCADIA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;12, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Wendy S. Neal</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Wendy S. Neal</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President&nbsp;&amp; Chief Legal Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consulting Services, Separation Agreement and Release between Arcadia Biosciences, Inc. and Eric J. Rey, dated February 11, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release issued by Arcadia Biosciences, Inc. entitled &#147;ARCADIA BIOSCIENCES ANNOUNCES DEPARTURE OF CEO FOR MEDICAL REASONS AND CHANGES IN BOARD OF DIRECTORS&#148; dated February 11, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d139618dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g139618ex10_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;11, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eric
Rey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Address] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Consulting Services, Separation Agreement and Release</U> </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Eric: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed, you and Arcadia Biosciences, Inc. (&#147;<B><I>Arcadia</I></B>&#148; or the &#147;<B><I>Company</I></B>&#148;) have mutually
agreed that your employment with Arcadia shall terminate effective as of March&nbsp;1, 2016 (the &#147;<B><I>Termination Date</I></B>&#148;). The purpose of this Consulting Services, Separation Agreement and Release letter
(&#147;<B><I>Agreement</I></B>&#148;) is to set forth the terms and conditions of your consulting services and the specific separation benefits that Arcadia will provide you in exchange for your agreement to the terms and conditions of this
Agreement. You and Arcadia agree that for the purpose of determining severance benefits, the termination of your employment shall be deemed a termination without cause pursuant to the Severance and Change in Control Agreement between you and the
Company executed on May&nbsp;11, 2015 (&#147;<B><I>2015 Severance Agreement</I></B>&#148;), and that the benefits set forth in Sections 2(a)-(d)&nbsp;and 3(a) of this Agreement are merely restating the termination without cause benefits of the 2015
Severance Agreement (and this Agreement is not intended to provide a double recovery of the same benefits). To the extent there is any inconsistency between this Agreement and the 2015 Severance Agreement, this Agreement shall govern and control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By your signature below, you agree to the following terms and conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>End of Employment and Consultant Service Period</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. <U>End of Employment</U>. You agree that you will cease to be President and Chief Executive Officer of the Company effective as of
February&nbsp;11, 2016, and that as of that date you also ceased to be a member of the Board of Directors of the Company (the &#147;<B><I>Board</I></B>&#148;). The Company has agreed, however, that your employment as an employee with Arcadia will
terminate on the Termination Date. After February&nbsp;11, 2016, you will not hold yourself out as representing the Company or otherwise attempt to bind the Company to any contractual arrangements. You acknowledge that you will reasonably cooperate
in removing yourself from any role in the Company or in any affiliated entity of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Consulting Services</U>. Following your Termination Date, you will continue to be available
to perform services for the Company (if requested by the Company) as a consultant to the Company. Your consulting relationship with the Company will continue until March 1, 2017; provided that either you or the Company may end your consulting
relationship at any time, for any reason, and provided further that you and the Company may agree to continue your consulting relationship beyond March 1, 2017 by entering into a new written consulting agreement with the Company. The period from the
Termination Date through March 1, 2017 or, if earlier, the last day of your service as a consultant to the Company, is referred to herein as the &#147;<B><I><U>Consultant Service Period</U></I></B>&#148;. During the Consultant Service Period, you
will be expected to permit the Company to learn about and use your knowledge, expertise, and experience gained during your employment and advise and assist the Company in the training and orientation of your replacement. The Company shall have the
right to consult with you, upon reasonable advance notice, for up to 10 hours each calendar month during the Consultant Service Period, provided that such consulting services shall not unreasonably interfere with your then-current activities, and
you shall exercise reasonable efforts to fulfill the Company&#146;s consulting requests in a timely manner, notwithstanding your personal and other business commitments. The Company knows, understands and agrees that you may perform the consulting
services under this Agreement off-site, by e-mail and/or by telephone and that your presence on-site is not required to perform the consulting services; provided further, however, upon reasonable request by the Company, you agree to participate in
on-site meetings periodically with the Company management or staff as part of performance of your consulting services. Your consulting services shall in no way prohibit or otherwise impair your right and ability to find and commence alternative
employment or to provide consulting services to another organization (subject to any existing confidentiality and nonsolicit obligations you owe to the Company, which shall be modified appropriately to reflect the fact that you may serve as a
consultant or employee to other entities during the Consultant Service Period). You will be fully indemnified by the Company and you will be covered by the Company&#146;s Director&#146;s &amp; Officers liability insurance coverage to the maximum
extent permitted by law for any services that you may be asked to render during the Consultant Service Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. <U>Consulting
Compensation</U>. You will be compensated during the Consultant Service Period for your services rendered at the rate of $500/hour. Your services as a Consultant may be requested only by the Company&#146;s President and CEO (or any Interim President
and CEO), the Replacement President and CEO, or the Board. During the Consultant Service Period, you shall continue to vest with respect to any outstanding options to purchase common stock of the Company, and Arcadia agrees that if Arcadia
terminates the Consultant Service Period prior to the date that you become fully vested in your outstanding options to purchase common stock of the Company, then your outstanding unvested options to purchase common stock of the Company shall fully
vest as of the date that the Consultant Service Period ends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. <U>Reimbursement of Consulting Expenses</U>. Pursuant to and in
accordance with the Company expense policies then in effect, the Company shall promptly reimburse you, upon receipt of reasonable documentation, for all out-of-pocket expenses necessarily incurred by you, including reasonable expenses for travel and
accommodations (but, in each case, only to the extent that you have been requested or authorized, in accordance with the terms hereof, to incur such expenses in relation to your consulting services) for the purpose of providing any consulting
services required hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 2
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">e. <U>Status as a Consultant</U>. You will not be, and will not be treated as, an employee of the
Company for any purpose with respect to such consulting services, including for purposes of any of the Company&#146;s benefit plans. You acknowledge and agree that as a consultant, you will be an independent contractor to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Accrued Benefits</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a.
Upon your receipt of your final paycheck on the Termination Date, which will include payment for services for the final payroll period through the Termination Date, you will have received all wages owed to you by virtue of your employment with
Arcadia or termination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. Upon your receipt of payment in the amount of $62,885, less required deductions and withholding, which
represents payment for 327 hours of accrued and unused vacation or personal-time-off as of the Termination Date at your regular rate, you will have received all other accrued compensation owed to you by virtue of your employment with Arcadia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. You acknowledge and agree and the Company agrees that you will be reimbursed for business expenses consistent with Company policy and
practice. You will submit any receipts for unreimbursed business expenses within 30 days of the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. The COBRA period for
continuation of your insurance coverage under Arcadia&#146;s group plans will begin on the first day of the month immediately following the Termination Date. Information regarding your right to elect COBRA coverage will be sent to you via separate
letter. Your rights to COBRA continuation coverage are set forth in the 2015 Severance Agreement, Section&nbsp;3(a)(iii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">e. You are not
eligible for any other payments or benefits by virtue of your employment with Arcadia or termination thereof except for those expressly described in this Agreement. You will receive the payments described in this Sections 2(a)-(c)&nbsp;whether or
not you sign this Agreement. You will receive the COBRA continuation benefit (other than as required by law) described in Section&nbsp;2(d) and the separation pay described in Sections 3 of this Agreement only if (i)&nbsp;you sign this Agreement and
do not revoke it as permitted below, and (ii)&nbsp;you do not violate any of the terms and conditions set forth in this Agreement. All payments and benefits described in this Agreement are subject to payroll taxes, withholdings, and deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Separation Pay and Benefits</U>. Specifically in consideration of your signing this Agreement, both in connection with the Termination
Date, and subject to the limitations, obligations, and other provisions contained in this Agreement, Arcadia agrees to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. pay you
severance as set forth in the 2015 Severance Agreement, Section&nbsp;3(a)(ii) (the &#147;<B><I>Cash Severance</I></B>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 3
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. extend the post-termination exercise period on all of your outstanding options to purchase
common stock of the Company (each an &#147;<B><I>Option</I></B>&#148; and collectively, the &#147;<B><I>Options</I></B>&#148;) to the original expiration date of the Option (i.e., 10 years from the date of grant) and such Options shall not terminate
earlier as a result of your termination of continuous service with the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. pay you a cash bonus for calendar year 2015 of
$60,000, which you acknowledge and agree is in full payment of any bonus payments under the Company&#146;s bonus plans or programs to which you may be entitled, which bonus will be paid the first payroll period following receipt by the Company of
your executed copy of this Agreement and the termination of any revocation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Release of Claims</U>. Specifically in
consideration of the separation pay, extension of the post-termination exercise period on your Options, benefits, consulting services arrangement, and other good and valuable consideration, and to which you would not otherwise be entitled, by
signing this Agreement you, for yourself and anyone who has or obtains legal rights or claims through you, agree to the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. You
hereby do release and forever discharge the &#147;<B><I>Released Parties</I></B>&#148; (as defined in Section&nbsp;4.e. below) of and from any and all manner of claims, demands, actions, causes of action, administrative claims, liability, damages,
claims for punitive or liquidated damages, claims for attorney&#146;s fees, costs and disbursements, individual or class action claims, or demands of any kind whatsoever, you have or might have against them or any of them, whether known or unknown,
in law or equity, contract or tort, arising out of or in connection with your employment with Arcadia, or the termination of that employment or otherwise, and however originating or existing, from the beginning of time through the date of your
signing this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. This release includes, without limiting the generality of the foregoing, any claims you may have for any of
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">wages, bonuses, commissions, penalties, deferred compensation, vacation, sick, and/or PTO pay, separation pay and/or benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">defamation of any kind including, but not limited to, libel, slander; invasion of privacy; negligence; emotional distress; breach of express, implied or oral contract; estoppel; fraud; intentional or negligent
misrepresentation; breach of any implied covenants; wrongful prosecution; assault or battery; negligent hiring, supervision or retention; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">wrongful discharge (based on contract, common law, or statute, including any federal, state or local statute or ordinance prohibiting discrimination or retaliation in employment); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">violation of any of the following: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the United States Constitution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the California Fair Employment and Housing Act,, Cal. Gov&#146;t Code &#167; 12900 <U>et seq.;</U> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the California Labor Code; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the California Business and Professions Code; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Title VII of the Civil Rights Act, 42 U.S.C. &#167; 2000e <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 <U>et seq</U>.; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 4
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Older Workers Benefit Protection Act, 29 U.S.C. &#167; 623 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Civil Rights Act of 1866, 42 U.S.C. &#167; 1981; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Civil Rights Act of 1991, 42 U.S.C. &#167; 1981a; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Americans with Disabilities Act, 42 U.S.C. &#167; 12101 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Genetic Information Nondiscrimination Act of 2008; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Employee Retirement Income Security Act of 1976, 29 U.S.C. &#167; 1001 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the National Labor Relations Act, 29 U.S.C. &#167; 151 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Worker Adjustment and Retraining Notification Act, 29 U.S.C. &#167; 2101 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Fair Credit Reporting Act, 15 U.S.C. &#167;&#167; 1681 <U>et seq</U>.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Sarbanes-Oxley Act, 15 U.S.C. &#167; 7201 <U>et seq</U>.; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other federal, state or local statute prohibiting discrimination in employment or granting rights to you arising out of the employment relationship with Arcadia or termination thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any claim for retaliation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any claim for discrimination or harassment based on sex, race, color, religion, age, national origin, disability, genetic information, or any other legally-protected class. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. You hereby waive any and all relief not provided for in this Agreement. You understand and agree that, by signing this Agreement, you waive
and release any claim to employment with Arcadia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. You are not, by signing this Agreement, releasing or waiving (i)&nbsp;any vested
interest you may have in any 401(k), pension, or profit sharing, or other Company benefit plan by virtue of your employment with Arcadia, (ii)&nbsp;any rights or claims arising under the Company&#146;s short term disability or long-term disability
plans, (iii)&nbsp;any rights or claims that may arise after the Effective Date, (iv)&nbsp;the post-employment separation pay and benefits specifically promised to you in Section&nbsp;2 or 3 of this Agreement and non-disparagement covenant set forth
in Section&nbsp;7(c) of this Agreement, (v)&nbsp;the right to institute legal action for the purpose of enforcing the provisions of this Agreement, (vi)&nbsp;the right to apply for state unemployment compensation benefits, (vi)&nbsp;the right to
file a charge of discrimination with a governmental agency such as the Equal Employment Opportunity Commission (although you agree that you will not be able to recover any award of money or damages if you file such a charge or have a charge filed on
your behalf) or to testify, assist, or participate in an investigation, hearing, or proceeding conducted by such an agency, or (vii)&nbsp;any rights you have under the Consolidated Omnibus Budget Reconciliation Act (&#147;<B><I>COBRA</I></B>&#148;).
For the avoidance of doubt, you are not releasing your common law, contractual, statutory or other rights to indemnification or coverage under the Company&#146;s Director&nbsp;&amp; Officer liability insurance policy or under your indemnification
agreement dated March&nbsp;24, 2015, arising from, or in connection with, your employment with, or service as an officer or director of, Arcadia, or in connection with your performance of consulting services hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">e. The &#147;<B><I>Released Parties</I></B>,&#148; as used in this Agreement, shall mean Arcadia and its related and affiliated entities and
subsidiaries, and its and their present and former officers, directors, shareholders, trustees, employees, agents, insurers, attorneys, representatives and consultants, and the successors and assigns of each, whether in their individual or official
capacities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 5
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Return of Property</U>. You acknowledge and agree that all documents and materials relating
to the business of, or the services provided by, Arcadia are the sole property of Arcadia. You agree and represent that, by 15 days after the Termination Date, (a)&nbsp;you will have returned to Arcadia all of its property (whether or not
confidential or proprietary), including but not limited to, all customer records, and all Arcadia documents, materials, emails, and texts concerning Arcadia from any and all personal media (including, but not limited to, personal computers,
Blackberries, PDA&#146;s, cell phones, etc.), whether on computer disc, hard drive or other form, and all copies thereof, within your possession or control, and (b)&nbsp;following your returning of all the above-described property, you then deleted
or otherwise destroyed all Arcadia-related information, including deleting such information from all your personal media. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.
<U>Confidential and Proprietary Information</U>. You acknowledge and agree that you have had access in your employment with Arcadia to confidential and proprietary information of Arcadia and further acknowledge and agree that the release or
disclosure of any confidential or proprietary information will cause Arcadia irreparable injury. You acknowledge that you have not used or disclosed (other than for Arcadia&#146;s sole benefit during your employment with Arcadia), and agree that you
will not at any time use or disclose, directly or indirectly, to any other entity or person, any confidential or proprietary information of Arcadia, unless such information becomes publicly known other than through your breach of this Agreement,
either directly or indirectly. ,. For purposes of this Agreement, the term &#147;confidential or proprietary information&#148; will include, but not be limited to, customer lists and information pertaining to customer lists; contact lists; and
information about the personal or business affairs of Arcadia&#146;s customers, vendors, or employees. You acknowledge and agree that you continue to be bound by the Employee Confidential Information and Inventions Agreement dated August&nbsp;14,
2003 between you and the Company (&#147;<B><I>Confidential Information Agreement&#148;)</I></B>, a copy of which is attached here to as <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Confidentiality; Non-Solicitation and Nondisparagement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Unless such information becomes publicly known other than through your breach of this Agreement, either directly or indirectly, you promise
and agree not to discuss or disclose, directly or indirectly, in any manner whatsoever, any information regarding either (i)&nbsp;the contents or terms of this Agreement, or (ii)&nbsp;the substance and/or nature of any dispute between Arcadia and
any employee or former employee, including yourself. You agree that the only people with whom you may discuss this confidential information are your legal and financial advisors and your spouse, if applicable, provided they agree to keep the
information confidential, or as required by law unless such information becomes public other than through breach of this Agreement by you, either directly or indirectly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. For the one year period following your Termination Date, you shall not directly or indirectly, personally or through others, solicit,
recruit or attempt to solicit or recruit (on your own behalf or on behalf of any other person or entity) either (i)&nbsp;any employee or any consultant of the Company or any of the Company&#146;s affiliates or (ii)&nbsp;the business of any customer
of the Company or any of the Company&#146;s affiliates on whom you called or with whom you became acquainted during your employment. You represent that you (i)&nbsp;are familiar with the foregoing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 6
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covenant not to solicit, and (ii)&nbsp;are fully aware of your obligations hereunder, including, without limitation, the reasonableness of the length of time, scope and geographic coverage of
these covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. You agree that your obligation under paragraph b above includes in particular your agreement that during Consultant
Service Period, you will not consult for Intrexon, Inc. in connection with its transactions, existing or proposed, with the Company; provided that nothing herein restricts your ability to work with any company on matters not involving the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. You promise and agree not to make or induce any other person to make derogatory or disparaging statements of any kind, oral or
written, regarding the Released Parties (as defined in Section&nbsp;4.e.) to any person or organization whatsoever. Arcadia shall direct the executive officers and directors of Arcadia not to make, or induce any other person to make, derogatory or
disparaging statements of any kind, oral or written, regarding you in a manner likely to be harmful to your business or personal reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">e. Nothing in this Section or elsewhere in this Agreement will limit (i)&nbsp;your or Arcadia&#146;s obligation to give truthful testimony or
information to a court or governmental agency when required to do so by subpoena, court order, law, or administrative regulation (including but not limited to making truthful statements in public filings as required by applicable law), or
(ii)&nbsp;your legal right to testify, assist, or participate in an investigation, hearing or proceeding conducted regarding a charge of discrimination filed with a governmental agency; provided, however, that you will not voluntarily assist or aid
any other party in connection with any claims adverse to Arcadia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Cooperation</U>. In further consideration for the Cash Severance
and other severance benefits described in this Agreement, you agree you will, at Arcadia&#146;s request and upon reasonable notice: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a.
Answer Arcadia&#146;s reasonable business-related inquiries within your knowledge and related to your employment with Arcadia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. Provide
assistance to, and fully cooperate with, Arcadia in connection with any claim, investigation, dispute, litigation, or proceeding arising out of matters within your knowledge and related to your employment with Arcadia at mutually agreeable times and
places. Your cooperation will include, but not be limited to, providing truthful information, declarations, and/or statements to Arcadia, meeting with attorneys or other representatives of Arcadia, and preparing for and giving depositions or
testimony. You agree to promptly notify Arcadia as immediately as possible if you are subpoenaed or otherwise required or asked to testify in any proceeding involving Arcadia. Arcadia agrees to reimburse you for your reasonable expenses associated
with any such cooperation, including reimbursing you for your reasonable and documented time spent providing such assistance at the same hourly rate as you will receive for consulting services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 7
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Remedies</U>. If you breach any term of this Agreement, Arcadia will be entitled to its
available legal and equitable remedies. If Arcadia breaches any term of this Agreement, you will be entitled to your available legal and equitable remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Non-Admission</U>. It is expressly understood that this Agreement does not constitute, nor will it be construed as an admission by
Arcadia or you of any liability or unlawful conduct whatsoever. Arcadia and you specifically deny any liability or unlawful conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Successors and Assigns</U>. This Agreement is personal to you and may not be assigned by you without the written agreement of Arcadia. For the avoidance of doubt, in the event of your death, any payments or benefits that you become entitled to
under this Agreement will be paid or provided to your estate. The rights and obligations of this Agreement will inure to the successors and assigns of Arcadia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Enforceability</U>. If a court finds any term of this Agreement to be invalid, unenforceable, or void, the parties agree that the court
will modify such term to make it enforceable to the maximum extent possible. If the term cannot be modified, the parties agree that the term will be severed and all other terms of this Agreement will remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Governing Law</U>. This Agreement will be governed and construed in accordance with the laws of the State of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Full Agreement</U>. This Agreement contains the full agreement between you and Arcadia and may not be modified, altered, or changed in
any way except by written agreement signed by both parties. The parties agree that this Agreement supersedes and terminates any and all other written and oral agreements and understandings between the parties; except that notwithstanding the
foregoing, at all times in the future, you will remain bound by the Confidential Information Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Acknowledgment of Reading
and Understanding</U>. By signing this Agreement, you acknowledge that you have read this Agreement, including the release of claims contained in Section&nbsp;4, and understand that the release of claims is a <B><U>full and final release of all
claims</U></B> you may have against Arcadia and the other entities and individuals covered by the release. By signing, you also acknowledge and agree that you have entered into this Agreement knowingly and voluntarily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Certain Information and Representations</U>. You hereby represent and warrant that you are unaware of (1)&nbsp;any claims that have
been threatened or asserted against the Company that are not already known to in-house legal counsel or (2)&nbsp;any fraud or suspected fraud involving the Company, management or other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Legal Fees</U>. Arcadia shall pay your reasonable attorney&#146;s fees and costs incurred by legal counsel chosen by you in connection
with negotiating and finalizing this Agreement, provided that such fees and costs do not exceed $10,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 8
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Section&nbsp;409A.</U> The severance benefits and other payments payable under this
Agreement are intended to qualify for an exemption from application of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, and any state law of similar effect (collectively&nbsp;&#147;Section 409A&#148;) or comply with its
requirements to the extent necessary to avoid adverse personal tax consequences under Section&nbsp;409A, and any ambiguities herein shall be interpreted accordingly. Severance benefits shall not commence until you incur a &#147;separation from
service&#148; for purposes of Section&nbsp;409A. Each installment of severance benefits is a separate &#147;payment&#148; for purposes of Treas. Reg. Section&nbsp;1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy the exemptions
from application of Section&nbsp;409A provided under Treasury Regulations Sections 1.409A-1(b)(4), <FONT STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and 1.409A-1(b)(9). If such exemptions, however, are not available and you are, upon separation
from service, a &#147;specified employee&#148; for purposes of Section&nbsp;409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section&nbsp;409A, the timing of the severance benefits payments shall be delayed
until the earlier of (i)&nbsp;six (6)&nbsp;months and one day after your separation from service, or (ii)&nbsp;your death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your service to
Arcadia. We wish you well in your future endeavors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARCADIA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Darby Shupp</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Darby Shupp</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>202 Cousteau Place
&#149; Suite 105 &#149; Davis, CA 95618 &#149; Tel: 530-756-7077 &#149; Fax: 530-756-7027 &#149; Web: <U>www.arcadiabio.com</U> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"> Page
 9
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ACKNOWLEDGMENT AND SIGNATURE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have up to 21 days after receipt of this Agreement within which to review it and to discuss it with an attorney of your own choosing, at your own expense,
whether or not you wish to sign it. Furthermore, you have 7 days after you have signed this Agreement during which time you may revoke this Agreement. If you wish to revoke this Agreement, you may do so by delivering a letter of revocation to Wendy
S. Neal, Vice President&nbsp;&amp; Chief Legal Officer, at 4222 East Thomas Road, Suite 320, Phoenix, AZ 85018, no later than the close of business on the 7th day after you sign this Agreement. Because of the revocation period, you understand that
this Agreement shall not become effective or enforceable until the 8th day after the date you sign this Agreement upon the condition that you shall not have revoked this Agreement during the 7-day revocation period. Before signing this Agreement,
you should make sure that you understand what you are signing, what benefits you are receiving, and what rights you are giving up, including your rights under the Age Discrimination in Employment Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By signing below, I, Eric Rey, acknowledge and agree to all of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I have had adequate time to consider whether to sign this Consulting Services, Separation Agreement and Release. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I have read this Consulting Services, Separation Agreement and Release carefully. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I understand and agree to all of the terms of the Consulting Services, Separation Agreement and Release. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I am knowingly and voluntarily releasing my claims against Arcadia and the other persons and entities defined as the Released Parties, except to the extent otherwise provided in Section&nbsp;4.d. of the Agreement.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I have not, in signing this Agreement, relied upon any statements or explanations made by Arcadia except as for those specifically set forth in this Consulting Services, Separation Agreement and Release.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I intend this Consulting Services, Separation Agreement and Release to be legally binding. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">I am signing this Consulting Services, Separation Agreement and Release on or after the Termination Date. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and agreed this &nbsp;&nbsp;&nbsp;&nbsp; day of February, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eric Rey</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL INFORMATION AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARCADIA BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EMPLOYEE CONFIDENTIAL INFORMATION AND </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INVENTIONS AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In partial
consideration and as a condition of my employment or continued employment with Arcadia Biosciences, Inc., (which together with any parent, subsidiary, affiliate, or successor is hereinafter referred to as the <B><I>&#147;Company&#148;), </I></B>and
effective as of the date that my employment with the Company first commenced, I hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>1.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Noncompetition. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During my employment with the Company, I will perform for the
Company such duties as it may designate from time to time and will devote my full time and best efforts to the business of the Company and will not, without prior written approval of (i)&nbsp;an officer of the Company if I am not an executive
officer of the Company or (ii)&nbsp;the Board of Directors of the Company if I am an executive officer of the Company, (a)&nbsp;engage in any other professional employment or consulting, or (b)&nbsp;directly or indirectly participate in or assist
any business which is a current or potential supplier, customer, or competitor of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>2.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Nonsolicitation. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the term of my employment by the Company, and for twelve
months thereafter, I shall not directly or indirectly, either alone or in concert with others, without the prior written consent of the Company, solicit, recruit, encourage or induce any employees, directors, consultants, contractors or
subcontractors of the Company to leave the employ of the Company, either on my own behalf or on behalf of any other person or entity. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>3.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Confidentiality Obligation. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I will hold all Company Confidential Information in
confidence and will not disclose, use, copy, publish, summarize, or remove from the premises of the Company any Confidential Information, except (a)&nbsp;as necessary to carry out my assigned responsibilities as a Company employee, and
(b)&nbsp;after termination of my employment, only as specifically authorized in writing by an officer of the Company. <B><I>&#147;Confidential Information&#148; </I></B>is all patient health information, information related to any aspect of the
business of the Company which is either information not known by actual or potential competitors of the Company or is proprietary information of the Company, whether of technical nature or otherwise. Confidential Information includes inventions,
disclosures, processes, systems, methods, formulae, devices, patents, patent applications, trademarks, intellectual properties, instruments, materials, products, patterns, complications, programs, techniques, sequences, designs, research or
development activities and plans, specifications, computer programs, source codes, mask works, costs of production, prices </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other financial data, volume of sales, promotional methods, marketing plans, lists of names or classes of customers or personnel, list of suppliers, business plans, business opportunities, or
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further I acknowledge that patients provide personal information with the expectation that it will be kept confidential and used
only by authorized persons as necessary. As such, I shall and agree that I must treat all services provided to patients as private and confidential. All personally identifiable information which may be provided by patients or regarding medical
services provided to patients, which the employee may be given access to while employed or affiliated with the Company and in whatever form such information may exist, including oral, written, printed photographic and electronic formats
(collectively, the &#147;Patient Health Information (PHI)&#148;) is strictly confidential and is protected by federal and state laws and regulations that prohibit its unauthorized use or disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, I agree that, except as authorized in connection with assigned duties, I will not at any time use, access or disclose any PHI to any person
(including but not limited to coworkers, friends and family members). I understand that this obligation remains in fall force during the entire term of my employment and continues in effect after such employment terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I acknowledge that I may be required to read, recognize and comply with additional legal confidentiality requirements as required by the Health Insurance
Portability and Accountability Act of 1996 (HIPAA). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>4.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Information of Others. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I will safeguard and keep confidential the proprietary
information of customers, vendors, consultants, and other parties with which the Company does business to the same extent as if it were Company Confidential Information. I will honor, and comply and act in accordance with, the terms and conditions
of any and every agreement entered into by the Company whereby the Company has agreed to keep confidential the proprietary information of others. I will not, during my employment with the Company or otherwise, use or disclose to the Company any
confidential, trade secret, or other proprietary information or material of any previous employer or other person, and I will not bring onto the Company&#146;s premises any unpublished document or any other property belonging to any former employer
without the written consent of that former employer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>5.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Company Property. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All papers, records, data, notes, drawings, files, documents,
samples, devices, products, equipment, or other materials, including copies and in whatever form, relating to the business of the Company that I possess or create as a result of my Company employment, whether or not confidential, are the sole and
exclusive property of the Company. In the event of the termination of my employment, I will promptly deliver all such materials to the Company and will sign and deliver to the Company the &#147;Termination Certificate&#148; attached hereto as
<U>Exhibit A.</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>6.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Ownership of Inventions. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All inventions, ideas, designs, circuits, schematics, formulas,
algorithms, trade secrets, works of authorship, mask works, developments, processes, techniques, improvements, and related know-how (including anything that derives actual or potential economic value from not being generally known to the public or
to other persons who can obtain economic value from its disclosure) which results from work performed by me, alone or with others, on behalf of the Company or from access to the Company Confidential Information or property whether or not patentable,
copyrightable, or qualified for mask work protection (collectively <B><I>&#147;Inventions&#148;) </I></B>shall be the property of the Company, unless otherwise documented by prior agreement in writing, and, to the extent permitted by law, shall be
&#147;works made for hire.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby assign and agree to assign to the Company or its designee, without further consideration my entire right,
title, and interest in and to all Inventions, other than those described in Paragraph 7 of this Agreement, including all rights to obtain, register, perfect, and enforce patents, copyrights, mask work rights, and other intellectual property
protection for Inventions. I will disclose promptly and in writing to the individual designated by the Company or to my immediate supervisor all Inventions which I have made or reduced to practice. During my employment and for four years after, I
will assist the Company (at its expense) to obtain and enforce patents, copyrights, mask work rights, and other forms of intellectual property protection on Inventions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>7.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Excluded Inventions. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attached as <U>Exhibit J3 </U>is a list of all inventions,
improvements, and original works of authorship which I desire to exclude from this Agreement, each of which has been made or reduced to practice by me prior to my employment by the Company </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>8.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Patent Applications. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company files an original United States patent
application covering any invention of which I am a named inventor, I will receive an inventor&#146;s fee of $100. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>9.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Prior Contracts. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I represent that there are no other contracts to assign
inventions that are now in existence between any other person or entity and me, unless otherwise noted in writing. I further represent that I have no other employments, consultancies, or undertakings which would restrict and impair my performance of
this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>10.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Agreements with the United States Government and Other Third Parties. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I
acknowledge that the Company from time to time may have agreements with other persons or with the United States Government or agencies thereof which impose obligations or restrictions on the Company regarding Inventions made during the course of
work under such agreements or regarding the confidential nature of such work. I agree to be bound by all such obligations or restrictions and to take all action necessary to discharge the obligations of the Company thereunder. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>11.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>No Employment Agreement. </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I agree that unless specifically provided in another
writing signed by me and an officer of the Company, my employment by the Company is not for a definite period of time. Rather, my employment relationship with the Company is one of employment at will and my continued employment is not obligatory by
either myself or the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>12.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Miscellaneous. </I></B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.1 Governing Law. </I></B>This Agreement shall be
governed by, and construed in accordance with, the laws of the State of Arizona excluding those laws that direct the application of the laws of another jurisdiction.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.2 Enforcement. </I></B>If any provision of this Agreement shall be determined to be invalid or unenforceable for any reason, it shall
be adjusted rather than voided, if possible, in order to achieve the intent for the parties to the extent possible. In any event, all other provisions for this Agreement, shall be deemed valid, and enforceable to the full extent possible.<B><I>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.3 Injunctive Relief; Consent to Jurisdiction. I </I></B>acknowledge and agree that damages will not be an adequate
remedy in the event of a breach of any of my obligations under this Agreement. I therefore agree that the Company shall be entitled (without limitation of any other rights or remedies otherwise available to the Company and without the necessity of
posting a bond) to obtain an injunction from any court of competent jurisdiction prohibiting the continuance or recurrence of any breach of this Agreement. I herby submit myself to the jurisdiction and venue of the courts of the State of Arizona for
purposes of any such action. I further agree that service upon me in any such action or proceeding may be made by first class mail, certified or registered, to my address as last appearing on the records of the Company.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.4 Mediation. </I></B>I further agree that the Company, at its option, may elect to submit any dispute or controversy arising out of
or related to this Agreement to mediation and that I will be required to participate in this mediation in good faith. The mediation will take place in Arizona utilizing a mediator mutually acceptable to all Parties. In the event the Parties cannot
agree on a mediator, each Party will chose a<B><I> </I></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mediator and these two mediators will in turn choose a third mediator to mediate the controversy. The mediator mediating the controversy shall have experience in mediating the issues which are
the subject of the mediation and shall be independent of both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.5 Attorney&#146;s Fees. </I></B>If any party seeks to
enforce its rights under this Agreement by legal proceedings or otherwise, the non prevailing party shall pay all costs and expenses of the prevailing party.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.6 Waiver. </I></B>The waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a
waiver of any subsequent breach of the same or any other provision hereof.<B><I> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.7 Binding Effect. </I></B>This
Agreement shall be binding upon and shall inure to the benefit of the successors, executors, administrators, heirs, representatives, and assigns of the parties.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.8 Headings. </I></B>The Section headings herein are intended for reference and shall not by themselves determine the construction or
interpretation of this Agreement.<B><I> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>12.9 Entire Agreement; Modifications.</I></B> This Employee Confidential Information
and Inventions Agreement, together with the terms of the Company Employee Personnel Manual, contain the entire agreement between the Company and the undersigned employee concerning the subject matter contained therein and supersede any and all prior
and contemporaneous negotiations, correspondence, understandings, and agreements, whether oral or written, respecting that subject matter. All modifications to this Agreement must be in writing and signed by the party against whom enforcement of
such modification is sought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>IN WITNESS WHEREOF,<B> </B>I<B></B> have executed this document as of the 14th day of August 2003.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RECEIPT ACKNOWLEDGED:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARCADIA BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Brandwein</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steven F. Brandwein</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">VP Finance &amp; Administration</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric J. Rey</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Employee Name &#151; Printed</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><U>EXHIBIT </U></I></B><B><U>A </U></B><B><I><U> </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCADIA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is to certify that I do not have in my possession, nor have I failed to return, any papers, records, data, notes, drawings, files,
documents, samples, devices, products, equipment, designs, computer programs, and other materials, including reproductions of any of the aforementioned items, belonging to Arcadia Biosciences, Inc., its subsidiaries, affiliates, successors, or
assigns, or its customers, vendors, consultants or other parties (together, the <B><I>&#147;Company&#148;)</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further certify that
I have complied with all the terms of the Company&#146;s Employee Confidential, Information and Inventions Agreement signed by me, including at the reporting of any Inventions (as defined therein) conceived or made by me (solely or jointly with
others) covered by that agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that , in compliance with the Employee Confidential Information and Inventions
Agreement, I will hold in confidence and will not disclose, use, copy, publish, or summarize any Confidential Information (as defined in the Employee Confidential Information and Inventions Agreement) of the Company or of any of its customers,
vendors, consultants, or other parties with which it does business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Employee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Type/Print Employee&#146;s
Name</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><U>EXHIBIT B </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Excluded Inventions, Improvements, and </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Original Works of Authorship) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>Title<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B></B>Date<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>Identifying Number<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>Or&nbsp;Brief&nbsp;Description<B></B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d139618dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g139618g79e49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FOR IMMEDIATE RELEASE </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Jeff Bergau </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jeff.bergau@arcadiabio.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+1-312-217-0419 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCADIA BIOSCIENCES ANNOUNCES DEPARTURE OF CEO FOR MEDICAL
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REASONS AND CHANGES IN BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DAVIS, Calif. (February 11, 2016) </B>&#150; Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company, today announced the departure of
president and CEO Eric Rey for medical reasons. Roger Salameh, company officer and vice president of business development, will serve as interim CEO as the company conducts a search for Rey&#146;s successor. Salameh has been an Arcadia senior
manager since 2003, serving in business development and management roles throughout his tenure at the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rey was a co-founder of Arcadia, serving
as president since 2003, and president and CEO since 2006. The company announced on January&nbsp;13, 2016 that he would take a short-term leave of absence to recover from a medical procedure to install a stent in his coronary artery. Based on
consultations with his personal medical team following the procedure, Rey will depart from his executive position and his role as a board director to focus his time and energy on an anticipated full recovery. He has agreed to continue to serve as a
consultant to the company throughout the CEO search process and installation of his long-term replacement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Building Arcadia alongside the
company&#146;s longstanding management team has been an accomplishment for which all of us can be proud,&#148; said Rey. &#147;I have the utmost confidence in Roger&#146;s ability to lead the company through this important transition, and the entire
management team&#146;s commitment and ability to execute the mission we worked together to create.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The entire Arcadia team wishes Eric the
very best and we are thankful to him for his vision and leadership, which were instrumental in creating a truly unique company with a powerful value proposition,&#148; said Board Chairman, Darby Shupp. &#147;The solid team Eric assembled remains
intensely focused on meeting its business goals and creating long-term shareholder value throughout the CEO search process and beyond.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company
also announced that Vic Knauf, Ph.D., Arcadia&#146;s chief scientific officer, will replace Mark Wong on the Board of Directors. Wong&#146;s departure comes as a result of outside professional commitments which have been building during his service
to Arcadia. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g139618g79e49.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wong said, &#147;I have very much enjoyed working alongside this board and the management team, and
appreciate the mission and goals it has set out to accomplish. I have confidence that Vic will be of great value to the board.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shupp noted,
&#147;Mark Wong has been a terrific asset to Arcadia. In addition to his decade of service on the board, he stepped in to lead the team during Eric Rey&#146;s short-term medical leave, and we are grateful for his efforts, especially given the time
commitments required from his other business activities. We sincerely thank him and wish him well.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Knauf has been Arcadia&#146;s chief
scientific officer since June 2005. He brings 30 years of experience in agricultural product and technology development to the board. He was a founder of Anawah, Inc., a food and agricultural research company that Arcadia acquired in 2005.
Previously, he was director of food and nutrition research for Monsanto Company and vice president of research at Calgene Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Arcadia
Biosciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences (NASDAQ: RKDA) develops
agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia&#146;s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat
Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia&#146;s nutrition traits and products are aimed at creating healthier ingredients and whole foods with
lower production costs. In 2014, the company was listed in the Global Cleantech 100 and was previously named one of MIT Technology Review&#146;s 50 Smartest Companies. For more information, visit <U>www.arcadiabio.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g139618ex10_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g139618ex10_1pg001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ B0#& P$1  (1 0,1 ?_$ +\  0 #  (# 0$!
M       ("0H'"P0%!@(! P$!  (" P$!              <(!08#! D" 1
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MFCR8EO*JL\EMX*JSQQBEJKU4>/G5ZFT0_P %M'IKPT 53I]>U=V[>' !_:W
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MMQ45-L=@*CJSBJUY,=@R4ND^W3@J7#'4+[JS6M-HX3B"'0ZBH>+A"+&<O5
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M$=A5*^7O#0[]Z[D,#Y6;(1RQU%4:EDQJZ4,S+]3$;-K;!-UU7*0#]">XCA4
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E(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g139618g79e49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g139618g79e49.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MN@B[Z,I:2OV>_O+4?=4[E_S^59T?=G*!%/231L5U&P4 % !0 4 % !0 4 %
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MUK.DZ ;QKW6+@@OC$<DY"C QP!0!Q^L7&CZ5/;WGAJ]9)U?#QJ6*D?C_ "H
M].M9OM%I#/C'F('QZ9&: '32I!"\TC!8XU+,3V H XCP?&^L:_J&OSKQN*1
M]L_X+@?C0!UNI:59ZM;&"\A61>Q_B7W![4 </H+/X=\0:CH<SDQ3(3&QXR0,
M@_B* +WPU_Y!U]_UU'\J (=?BN?#_BZ/7TA:6TDP)-O\/&TCVXY% '1P^+="
MFA$@U&-./NOD$?A0!R7B'4+;4/$NFS74K2:(P!5AG:<$AOUZ^U &WJNKZ##H
M\]KIP@FFEB9(XK9 3R.O'3'6@#EK72IM3\";[92\MK=,Y0=2I49Q^E '7:-X
MQTNXTZ(75RMM<1J%D23CD=Q0!S/C/5XM7EM'M$9K.!ROGD85F..!] * +VI_
M\E,TW_<3^1H JZ/-8_\ "5:@_B,J+D-^[^T?<'/OQTQB@"3QMJFG7FGQ6VFJ
MLHCD#22Q)\B\$ 9]3_2@#NM+(.D61'3R$_\ 010!9>-)$9)$#HPP589!H ;#
M!#;Q[((DB3.=J* /TH /.B\WRO,7S/[N>?RIV=K@1R6]G)<JTL,+SXRI906P
M/3OWI )&ME8GRXU@M]W.U0%S32; FE:-8SYI4(>/FZ&E:X%%]%T<$S/I]H,<
MEC&N* )_LUC<VHA\B&2 =$V J/PHM8!EI8Z;:Q&2TMK>.-@<M&H (^M.W0":
MUCM8H?\ 1(XDC//[M0 ??BE:P%9M-TB^D$[6EK.QY#[%;/X]Z;36X$TD-@X2
MVDBMV"?=C90=OT':BSW 62&R%S'))%#]H_@9E&[CT/6BS 9>V.G7)4WMM!(W
M13(H)_6BUP)!86:V_P!G%I"(<Y\ORQM_*D!.JK&@1%"JHP !@ 4 +0 4 4CI
MD9U+[=O<29!P.G Q_6KYWR\HK:W)FME:]2Z).]$* =L$@_TJ;Z6"VI#<Z9%<
MO,Q=E$Z".0#'(&?RZFJ4VK>0-$MU:1W=MY#\+Q@]QCT]Z49<KN#5PGLTGLOL
MKLY7 ^;/.1@@_I0I6=PMI8EC5D7#OO/KC%)C(8;*.#3_ +&K,4VE<GKS_P#K
MIN5W<5K*P^UMQ:VJ0*Q*HH4'&.*3=W<$K$5KIT%G,TL(*EE"L,\''?'K3<FU
M9@E8<EH(KF6:.1AYK!G7 .2!C\.E'-=6"P3V:S74%QO*O"&"\<<X_P *%*R:
<"P7EDEZJ*[%2AR&7A@?8]J(RY0:N6:D84 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
